Changing trends in the treatment of dry-eye disease

Murat Dogru, Masatsugu Nakamura, Jun Shimazaki, Kazuo Tsubota

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Introduction: Dry eye is a visually disabling disease encountered in many countries with a wide variation of treatment practices all over the world. On that front, the 2007 Report of the International Dry Eye WorkShop (DEWS) reviewed the current knowledge on all aspects of dry-eye disease (DED), in an evidence-based manner, and outlined the trends and recommendations in the treatment of DED on the basis of disease severity. Areas covered: This review mainly focuses on treatments for DED based on severity as recommended in the DEWS report, particularly artificial eye drops, hyaluronate sodium eye drops, autologous serum, anti-inflammatory eye drops including cyclosporine and steroids, and mucin secretagogues. New dry-eye treatment modalities in current trials outlined on the clinicaltrial.gov site are also outlined. Expert opinion: Further investigations into the mechanism of action of the new mucin and tear secretagogues which have been suggested to have anti-inflammatory properties will enrich our understanding in relation to relevant ocular surface responses after treatment with these new agents.

Original languageEnglish
Pages (from-to)1581-1601
Number of pages21
JournalExpert Opinion on Investigational Drugs
Volume22
Issue number12
DOIs
Publication statusPublished - 2013 Dec

Fingerprint

Eye Diseases
Ophthalmic Solutions
Mucins
Anti-Inflammatory Agents
Artificial Eye
Education
Expert Testimony
Hyaluronic Acid
Tears
Cyclosporine
Steroids
Serum

Keywords

  • Artificial eye drops
  • Autologous serum
  • Dry-eye disease
  • Mucin secretagogues
  • Tear secretagogues

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Changing trends in the treatment of dry-eye disease. / Dogru, Murat; Nakamura, Masatsugu; Shimazaki, Jun; Tsubota, Kazuo.

In: Expert Opinion on Investigational Drugs, Vol. 22, No. 12, 12.2013, p. 1581-1601.

Research output: Contribution to journalArticle

Dogru, Murat ; Nakamura, Masatsugu ; Shimazaki, Jun ; Tsubota, Kazuo. / Changing trends in the treatment of dry-eye disease. In: Expert Opinion on Investigational Drugs. 2013 ; Vol. 22, No. 12. pp. 1581-1601.
@article{cfa8e5d6600441e4af837c44cb862016,
title = "Changing trends in the treatment of dry-eye disease",
abstract = "Introduction: Dry eye is a visually disabling disease encountered in many countries with a wide variation of treatment practices all over the world. On that front, the 2007 Report of the International Dry Eye WorkShop (DEWS) reviewed the current knowledge on all aspects of dry-eye disease (DED), in an evidence-based manner, and outlined the trends and recommendations in the treatment of DED on the basis of disease severity. Areas covered: This review mainly focuses on treatments for DED based on severity as recommended in the DEWS report, particularly artificial eye drops, hyaluronate sodium eye drops, autologous serum, anti-inflammatory eye drops including cyclosporine and steroids, and mucin secretagogues. New dry-eye treatment modalities in current trials outlined on the clinicaltrial.gov site are also outlined. Expert opinion: Further investigations into the mechanism of action of the new mucin and tear secretagogues which have been suggested to have anti-inflammatory properties will enrich our understanding in relation to relevant ocular surface responses after treatment with these new agents.",
keywords = "Artificial eye drops, Autologous serum, Dry-eye disease, Mucin secretagogues, Tear secretagogues",
author = "Murat Dogru and Masatsugu Nakamura and Jun Shimazaki and Kazuo Tsubota",
year = "2013",
month = "12",
doi = "10.1517/13543784.2013.838557",
language = "English",
volume = "22",
pages = "1581--1601",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Changing trends in the treatment of dry-eye disease

AU - Dogru, Murat

AU - Nakamura, Masatsugu

AU - Shimazaki, Jun

AU - Tsubota, Kazuo

PY - 2013/12

Y1 - 2013/12

N2 - Introduction: Dry eye is a visually disabling disease encountered in many countries with a wide variation of treatment practices all over the world. On that front, the 2007 Report of the International Dry Eye WorkShop (DEWS) reviewed the current knowledge on all aspects of dry-eye disease (DED), in an evidence-based manner, and outlined the trends and recommendations in the treatment of DED on the basis of disease severity. Areas covered: This review mainly focuses on treatments for DED based on severity as recommended in the DEWS report, particularly artificial eye drops, hyaluronate sodium eye drops, autologous serum, anti-inflammatory eye drops including cyclosporine and steroids, and mucin secretagogues. New dry-eye treatment modalities in current trials outlined on the clinicaltrial.gov site are also outlined. Expert opinion: Further investigations into the mechanism of action of the new mucin and tear secretagogues which have been suggested to have anti-inflammatory properties will enrich our understanding in relation to relevant ocular surface responses after treatment with these new agents.

AB - Introduction: Dry eye is a visually disabling disease encountered in many countries with a wide variation of treatment practices all over the world. On that front, the 2007 Report of the International Dry Eye WorkShop (DEWS) reviewed the current knowledge on all aspects of dry-eye disease (DED), in an evidence-based manner, and outlined the trends and recommendations in the treatment of DED on the basis of disease severity. Areas covered: This review mainly focuses on treatments for DED based on severity as recommended in the DEWS report, particularly artificial eye drops, hyaluronate sodium eye drops, autologous serum, anti-inflammatory eye drops including cyclosporine and steroids, and mucin secretagogues. New dry-eye treatment modalities in current trials outlined on the clinicaltrial.gov site are also outlined. Expert opinion: Further investigations into the mechanism of action of the new mucin and tear secretagogues which have been suggested to have anti-inflammatory properties will enrich our understanding in relation to relevant ocular surface responses after treatment with these new agents.

KW - Artificial eye drops

KW - Autologous serum

KW - Dry-eye disease

KW - Mucin secretagogues

KW - Tear secretagogues

UR - http://www.scopus.com/inward/record.url?scp=84887798602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887798602&partnerID=8YFLogxK

U2 - 10.1517/13543784.2013.838557

DO - 10.1517/13543784.2013.838557

M3 - Article

VL - 22

SP - 1581

EP - 1601

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 12

ER -